spacer
The Healthcare Sales & Marketing Network celebrates 27 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  Factor Xa inhibitor 

 HSMN NewsFeed - 5 Mar 2021
PACT Pharma Announces Planned Retirement of CEO Alex Franzusoff; Veteran Biotech Executive Scott Garland Named as Successor
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 14 May 2020
U.S. Centers for Medicare & Medicaid Services (CMS) Proposes Extending New Technology Add-on Payment (NTAP) Reimbursement for Portola Pharmaceuticals' Andexxa(R) for Third Year
Biopharmaceuticals Reimbursement
 HSMN NewsFeed - 12 May 2020
CytoSorb(R) is E.U. Approved to Remove Rivaroxaban, a Leading Factor Xa Inhibitor and Novel Oral Anticoagulant, During On-Pump Cardiothoracic Surgery
Devices Regulatory
 HSMN NewsFeed - 5 Mar 2020
New Data Demonstrates Andexxa(R) Can Provide a Net Cost Reduction for the Treatment of Intracranial Hemorrhage Associated with Oral Factor Xa Inhibitors
Biopharmaceuticals
 HSMN NewsFeed - 3 Feb 2020
Portola Pharmaceuticals Appoints Rajiv Patni, M.D., as Executive Vice President and Chief Medical Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 27 Aug 2018
Janssen Announces Results from MARINER and COMMANDER HF Studies
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 23 Mar 2018
Portola Pharmaceuticals Receives and Plans to Appeal Negative CHMP Opinion Regarding Marketing Authorization for Betrixaban in the European Union
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 30 Oct 2017
FDA Approves New 10 mg Dosing for XARELTO(R) (rivaroxaban) to Reduce the Continued Risk of Venous Thromboembolism (VTE)
Biopharmaceuticals FDA
 HSMN NewsFeed - 15 Nov 2016
Portola Pharmaceuticals Announces Three Phase 3 APEX Substudy Results Showing Further Benefits of Treating Acute Medically Ill Patients with Extended-Duration Betrixaban
Biopharmaceuticals
 HSMN NewsFeed - 30 Aug 2016
Portola Pharmaceuticals Announces Interim Results from Ongoing Phase 3b/4 ANNEXXA-4(TM) Study of Factor Xa Inhibitor Antidote AndexXa(TM) (andexanet alfa) in Patients with Acute Major Bleeding
Biopharmaceuticals
 HSMN NewsFeed - 26 Aug 2016
Portola Pharmaceuticals Announces Presentation of Interim Results from Phase 3b/4 ANNEXA(TM)-4 Study of AndexXa(TM) (andexanet alfa) at European Society of Cardiology 2016 Congress
Biopharmaceuticals
 HSMN NewsFeed - 19 Aug 2016
Portola Pharmaceuticals Announces Validation of Marketing Authorization Application (MAA) by European Medicines Agency (EMA) for IndexXa(TM) (andexanet alfa), a Factor Xa Inhibitor Antidote
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 18 Aug 2016
Portola Pharmaceuticals Receives Complete Response Letter from FDA for Biologics License Application for AndexXa(TM) (andexanet alfa)
Biopharmaceuticals FDA
 HSMN NewsFeed - 27 May 2016
Portola Pharmaceuticals Announces Full Results of Phase 3 APEX Study of Betrixaban Presented at International Society on Thrombosis and Haemostasis (ISTH) Meeting
Biopharmaceuticals
 HSMN NewsFeed - 27 Jun 2014
Eliquis(R) (apixaban) Receives CHMP Positive Opinion for the Treatment of Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE), and Prevention of Recurrent DVT and PE
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 31 Mar 2014
Daiichi Sankyo Initiates Phase 3 ENSURE-AF Study, Investigating Once-Daily Edoxaban in Patients with Atrial Fibrillation Undergoing Cardioversion
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 18 Mar 2014
Portola Pharmaceuticals Appoints John H. Johnson to Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 21 Feb 2014
In a Subanalysis, Eliquis(R) (apixaban) Reduced the Risk of Stroke and Demonstrated Fewer Major Bleeding Events versus Warfarin Consistently across Age Groups, Including Older Patients with Nonvalvular Atrial Fibrillation
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 13 Jan 2014
Portola Pharmaceuticals Enters Second Clinical Collaboration Agreement With Bristol-Myers Squibb and Pfizer to Study Andexanet Alfa* (PRT4445), Investigational Factor Xa Inhibitor Reversal Agent, With Eliquis
Biopharmaceuticals
 HSMN NewsFeed - 3 Sep 2013
Subanalysis of Phase III ARISTOTLE Trial of Eliquis(R) (apixaban) Demonstrated Consistent Results Versus Warfarin in Patients with Nonvalvular Atrial Fibrillation with or without Valvular Heart Disease
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 26 Dec 2012
ELIQUIS(R) (apixaban) Approved In Japan For The Prevention Of Stroke And Systemic Embolism In Patients With Nonvalvular Atrial Fibrillation
Biopharmaceuticals Cardiology Regulatory
 HSMN NewsFeed - 9 May 2012
Janssen Research & Development Submits Supplemental New Drug Application to U.S. FDA for XARELTO(R) (rivaroxaban) to Reduce the Risk of Stent Thrombosis in Patients with Acute Coronary Syndrome
Biopharmaceuticals Cardiology FDA
 HSMN NewsFeed - 13 Dec 2011
Edoxaban Significantly Reduces Risk of Venous Thromboembolism by Half Compared to Enoxaparin in Japanese and Taiwanese Patients Following Knee or Hip Arthroplasty Surgery
Biopharmaceuticals
 HSMN NewsFeed - 8 Sep 2011
FDA Advisory Committee Recommends Approval of Oral Anticoagulant Rivaroxaban for the Prevention of Stroke and Systemic Embolism in Patients with Non-Valvular Atrial Fibrillation
Biopharmaceuticals Cardiology FDA
 HSMN NewsFeed - 20 May 2011
ELIQUIS(R) (apixaban) Approved In Europe For Preventing Venous Thromboembolism After Elective Hip Or Knee Replacement
Biopharmaceuticals Surgery Orthopaedic
 HSMN NewsFeed - 22 Apr 2011
Daiichi Sankyo Receives First Market Approval in Japan for LIXIANA(R) (edoxaban), a Direct Oral Factor Xa Inhibitor, for the Prevention of Venous Thromboembolism after Major Orthopedic Surgery
Biopharmaceuticals Surgery Regulatory
 HSMN NewsFeed - 12 Apr 2011
Portola Pharmaceuticals Appoints Dr. James Topper to Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 22 Dec 2010
Newly Published Investigational Apixaban ADVANCE-3 Study Results Demonstrate Statistical Superiority to Enoxaparin with Comparable Rates of Bleeding in the Prevention of Venous Thromboembolism Following Total Hip Replacement Surgery
Biopharmaceuticals Orthopaedic Surgery
 HSMN NewsFeed - 15 Nov 2010
Rivaroxaban Significantly Reduces Risk of Stroke in Patients With Atrial Fibrillation With Comparable Safety vs. Warfarin in Pivotal Phase 3 Study
Biopharmaceuticals Cardiology Neurology
 HSMN NewsFeed - 23 Sep 2010
Portola Pharmaceuticals Appoints Jean-Jacques Bienaime to Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 31 Aug 2010
Rivaroxaban Successfully Demonstrated Non-Inferiority Compared to Standard of Care for the Prevention of Recurrent Venous Thromboembolism in Pivotal Phase 3 Study
Biopharmaceuticals
 HSMN NewsFeed - 11 Mar 2010
Portola Pharmaceuticals Announces Senior Management and Board Changes
Biopharmaceuticals Personnel
 HSMN NewsFeed - 24 Sep 2009
Portola Pharmaceuticals Announces Promotions of Senior Management Team
Biopharmaceuticals Personnel
 HSMN NewsFeed - 9 Jul 2009
Merck & Co., Inc. and Portola Enter Worldwide License Agreement to Develop and Commercialize Betrixaban, a Novel Investigational Oral Anticoagulant for Cardiovascular Disease
Biopharmaceuticals Licensing
 HSMN NewsFeed - 9 Dec 2008
Portola Pharmaceuticals Initiates Phase II Trial of Novel IV and Oral Anti-Platelet Drug in Non-Urgent Percutaneous Coronary Intervention
Biopharmaceuticals Interventional Cardiology
 HSMN NewsFeed - 2 Sep 2008
New Data is Presented on Investigational Oral Anticoagulant Apixaban in Acute Coronary Syndrome Patients
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 9 Jul 2008
Portola Completes $60 Million Financing to Advance Its Therapeutic Programs
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 24 Jun 2008
Portola Pharmaceuticals Names William Lis Vice President of Business Development and Commercial Operations
Biopharmaceuticals Personnel
 HSMN NewsFeed - 30 May 2008
Rivaroxaban Superior to U.S.-Approved Dosing Regimen for Enoxaparin in Reducing Venous Blood Clots after Total Knee Replacement Surgery in Pivotal Phase III Trial
Biopharmaceuticals Orthopaedic Surgery
 HSMN NewsFeed - 8 Dec 2007
Pivotal Phase III Data Showed Rivaroxaban Was Statistically Superior to Enoxaparin in Preventing Venous Thromboembolism (VTE) in Patients Following Hip Replacement Surgery
 HSMN NewsFeed - 5 Dec 2007
Bristol-Myers Squibb Company Outlines Strategy and Productivity Transformation Initiative During Update to Investment Community
Biopharmaceuticals
 HSMN NewsFeed - 8 Jul 2007
Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
Biopharmaceuticals
 HSMN NewsFeed - 7 May 2007
Portola Pharmaceuticals, Inc. Announces Completion of $70 Million Series C Financing
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 26 Apr 2007
Bristol-Myers Squibb and Pfizer Announce Worldwide Collaboration to Develop and Commercialize Anticoagulant and Metabolic Compounds
Biopharmaceuticals
 HSMN NewsFeed - 4 Apr 2007
Portola Pharmaceuticals Announces Positive Phase II Results for PRT054021 for Prevention of Venous Thromboembolism Following Total Knee Replacement Surgery
Biopharmaceuticals
Return to NewsFeed  

 Additional items found! 11

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 11 additional stories matching:
Factor Xa inhibitor
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.